Biohaven (BHVN.US) depression drug mid-stage trial failed, after-hours down 16%

According to the latest news from the Securities Times app, Biohaven (BHVN.US) announced on Wednesday that its experimental antidepressant did not meet its primary goal in a mid-stage trial. This is the latest setback in a series of trials and regulatory obstacles the company has faced this year. The company's stock dropped 16% in after-hours trading, and its total decline for the year has exceeded 70%.